



**Figure S1.** Effects of ASA pre-medication on the modified symptom scores 1 and 3.
**(A)** Number of recorded symptom score 1; **(B)** Number of recorded symptom score 3 at each time point during the 90-min monitoring period after oral OVM challenge combined with and without 30-min-ASA-pre-medication at 50 mg/kg in OVM sensitized mice (detailed data for Figure 5). ($n$ = 6–8/group)